Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and its Metabolite

Trial Identifier: ACE-HI-102
Sponsor:Acerta Pharma BV
Start Date:November 2018
Primary Completion Date: March 2019
Study Completion Date: March 2019
Condition: Healthy Volunteers; Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

USA, Florida Miami, Florida, USA, 33136
USA, Florida Orlando, Florida, USA, 32809
USA, Tennessee Knoxville, Tennessee, USA, 37920